Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published:2010-05 Issue: Volume:21 Page:v137-v139
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Escudier B.,Kataja V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/suppl_5/v137/484479/mdq206.pdf

Reference15 articles.

1. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;Gupta;Cancer Treat Rev,2008

2. Prognostic significance of morphologic parameters in renal cell carcinoma;Fuhrman;Am J Surg Pathol,1982

3. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009

4. The role of cytoreductive nephrectomy in the era of molecular targeted therapies;Polcari;Int J Urol,2009

5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of renal cell carcinoma in the transplanted kidney in renal transplant recipients: a systematic scoping review;Baylor University Medical Center Proceedings;2024-07-16

2. Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study;Cancer Medicine;2023-12-22

3. Optimal sequential therapy using tyrosine kinase inhibitors as the 1st-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study;Asian Journal of Urology;2023-03

4. Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature;BMC Cancer;2022-04-09

5. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists;Frontiers in Oncology;2022-01-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3